Mateon Therapeutics Inc  

(Public, OTCMKTS:MATN)   Watch this stock  
Find more results for NASDAQ:OXGN
0.234
-0.002 (-0.68%)
Delayed:   1:46PM EST
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.22 - 0.24
52 week 0.16 - 0.89
Open 0.22
Vol / Avg. 50,018.00/30,210.00
Mkt cap 6.21M
P/E     -
Div/yield     -
EPS -0.55
Shares 26.54M
Beta 1.57
Inst. own 11%
Nov 14, 2017
Q3 2017 Mateon Therapeutics Inc Earnings Release
Sep 12, 2017
Mateon Therapeutics Inc at Rodman & Renshaw Global Investment Conference
  

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -186.53% -65.70%
Return on average equity -224.38% -72.15%
Employees 13 -
CDP Score - -

Address

701 Gateway Blvd Ste 210
SOUTH SAN FRANCISCO, CA 94080-7041
United States - Map
+1-650-6357000 (Phone)
+1-650-6357001 (Fax)

Website links

Description

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor's blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

Officers and directors

William D. Schwieterman M.D. Chairman of the Board, President, Chief Executive Officer
Age: 58
Matthew M. Loar CPA Chief Financial Officer, Principal Accounting Officer
Age: 51
David Chaplin Ph.D. Chief Scientific Officer, Director
Age: 59
Simon C Pedder Ph.D. Director
Age: 56
Donald R. Reynolds Independent Director
Age: 54
Bobby W. Sandage Jr., Ph.D. Independent Director
Age: 63